ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
|Articles|September 13, 2019
Collaboration Aims to Drive Commercialization of Next-Generation Therapies
Author(s)BioPharm International Editors
TrakCel and McKesson have formed a collaboration that is aimed at accelerating commercialization of cell and gene therapies by leveraging services to enable a more efficient development pathway.
Advertisement
In a Sep. 11, 2019 press release, TrakCel and McKesson have formed a collaboration that is aimed at accelerating commercialization of cell and gene therapies by leveraging services to enable a more efficient development pathway.
Under the terms of the collaboration, the companies will integrate TrakCel’s data tracking and personalized medicine orchestration software system and McKesson’s high-touch patient platform to provide an end-to-end solution. After the companies have developed an initial solution design, it will be offered to clients on an individual basis, depending on whether it will be beneficial.
“TrakCel and McKesson have committed to working closely with a variety of current and future clients to specifically develop tailor-made solutions,” said Ravi Nalliah, CEO of TrakCel. “This integration of solutions and expertise with McKesson will enable us to continue to meet the needs of the cell and gene therapy sector and patients as more products move towards commercialization.”
“Precision medicine and the delivery of innovative cell and gene therapies require a personalized approach,” said Layne Martin, VP/GM, Specialty Distribution Solutions, McKesson Life Sciences. “TrakCel’s robust data tracking and verification capabilities, combined with McKesson’s industry leading 3PL, specialty pharmacy solutions and patient support capabilities, are critical to helping manufacturers safely and effectively commercialize innovative new therapies. This integrated system will help prescribers and manufacturers work together seamlessly to ensure that the right patient always receives the correct therapeutic product at the right time.”
Source:
Advertisement
Related to this article
More monoclonal antibodies are moving from IV infusion to subcutaneous injection, but dose, volume, and viscosity still limit the switch. This FAQ covers the formulation science, the enabling technologies, what regulators require, and what remains unresolved.
UCB will use Cradle’s AI-driven protein design platform in selected discovery projects, from hit generation through preclinical readiness, expanding its digital antibody engineering program.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5